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Abstract: Multiple drug resistant fungi pose a serious threat to human health, therefore the
development of completely new antimycotics is of paramount importance. The in vitro antifungal
activity of the original, 1-amino-5-isocyanonaphthalenes (ICANs) was evaluated against reference
strains of clinically important Candida species. Structure-activity studies revealed that the naphthalene
core and the isocyano- together with the amino moieties are all necessary to exert antifungal activity.
1,1-N-dimethylamino-5-isocyanonaphthalene (DIMICAN), the most promising candidate, was tested
further in vitro against clinical isolates ofCandida species, yielding a minimum inhibitory concentration
(MIC) of 0.04–1.25 µg/mL. DIMICAN was found to be effective against intrinsically fluconazole
resistant Candida krusei isolates, too. In vivo experiments were performed in a severly neutropenic
murine model inoculated with a clinical strain of Candida albicans. Daily administration of 5 mg/kg
DIMICAN intraperitoneally resulted in 80% survival even at day 13, whereas 100% of the control
group died within six days. Based on these results, ICANs may become an effective clinical lead
compound family against fungal pathogens.
Keywords: multiple drug resistance; antifungal effect; 1-amino-5-isocyanonaphthalenes;
1,1-N-dimethylamino-5-isocyanonaphthalene; Candida species; C. albicans
1. Introduction
Invasive fungal infections cause 1.5 million deaths annually and may show a further increase in
the following decades. Most of these infections are caused by Candida species, followed by Aspergillus
and Cryptococcus neoformans [1–3].
Members of the Candida genus are part of the healthy human microbiome and can be found in the
oral cavity, gastrointestinal and urogenital tract, however as opportunistic pathogens, these yeasts
can cause a wide variety of diseases ranging from superficial infections to life threatening invasive
candidiasis [4–6]. Incidence and mortality of the latter remained high in the last decades, despite
the widespread use of echinocandins and newer generation triazoles as prophylactic and therapeutic
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agents [7,8]. The development of invasive candidiasis is associated with several predisposing factors,
notably with immunosuppression, recent abdominal surgery, diabetes, broad spectrum antibiotic
therapy and many others [9]. While risk factors are numerous, therapeutic options are very limited
with only three major antifungal classes (triazoles, polyenes, echinocandins) available [10]. The most
recent antifungal compounds, the echinocandins were introduced almost twenty years ago and there
are few new drugs in the pipeline in the following years [11]. It should also be noted that several
strains of the Candida species, such as Candida krusei exhibit intrinsic resistance to fluconazole, however
despite their potential to emerge as multidrug-resistant pathogens in the hospital setting, this has not
yet occurred [1]. Nevertheless, the emergence of new, drug resistant pathogenic fungi, such as Candida
auris pose a serious therapeutic challenge and highlights the need for new compounds with different
mechanisms of action [12,13].
Recently, we developed a novel amino-isocyanonaphthalene (ICAN) based solvatochromic
fluorophore family [14], which despite their very simple structure and easy preparation, still mark a
white spot on the map of chemistry. Despite their relative novelty, they already found numerous and
versatile use in both analytical chemistry [15–17] and cell-biology [18–20]. During our experiments
to utilize ICAN derivatives as vital stains on CaCo2, OCM-1, HuLi and HaCat cell lines [20] we
noticed that they are perfectly suitable for the staining of different fungi, too. However, after testing
1-N-methylamino-5-isocyanonaphthalene (MICAN) on a commercial strain of Saccharomyces cerevisiae,
a strong antimycotic effect was observed. We wondered that ICAN derivatives could be used as
potential drugs against pathological fungi, and planned experiments on Candida species were started.
The aims of this study were to test the antifungal activity of 1-amino-5-isocyanonaphthalene
and its derivatives on different Candida species in vitro and to test the most effective agent in vivo,
in a murine model of invasive candidiasis. This discovery can lead to the development of a new
original compound family, which can rival the currently approved drug classes or even top them in
several fields of application. It should be noted, however that this study focuses only on the 1,5-ICAN
derivatives, whereas ICANs are easy to modify and even the slightest change in the relative substitution
position of the amino and isonitrile groups on the naphthalene ring can result in a completely different
behavior [21].
2. Results
2.1. Antifungal Activity of the ICAN Derivatives
We previously carried out extensive studies to successfully utilize 1-N-methylamino-5-
isocyanonaphthalene (MICAN) as a vital cell dye on different human cell lines [20]. The compound
along with ICAN and 1,1-N-dimethylamino-5-isocyanonaphthalene (DIMICAN) are well tolerated by
human cell cultures, their LD50 values (on HaCat cell line) were determined (MTT bio assay technique)
to be 10 µg/mL for ICAN, 18 µg/mL for MICAN, and 13 µg/mL for DIMICAN. Encouraged by these
results we wanted to extend their applicability to fungal staining. Since these dyes are nonpolar,
they are expected to easily bind to and stain the nonpolar chitin in the cell wall of different fungal
species. We tested this assumption on common yeast from a local shop, and much to our surprise after
staining, the yeast cells stopped growing and died in a short time. Repeated experiments led to the
same conclusion; however, the applied dye concentration was well below the LD50 determined for
human cells. We assumed that these compounds may have antifungal effect, therefore Candida albicans,
one of the most common human pathogenic fungi was selected for further tests. HaCat cell cultures
were infected with C. albicans and were treated with different concentrations of MICAN dissolved in
DMSO. The fungal growth was followed by time lapse imaging for 24 h. The results are summarized
in Figure 1. As it is evident from Figure 1a,b, contrary to the untreated (DMSO control) cells, which
show the typical yeast growth curve (Figure 1b), little fungal growth (~30 % of the starting C. albicans
cells even germinated) was observed at even as low as 7.5 µg/mL MICAN concentrations, which is
well below its LD50 value on HaCat cells. It should be noted, however, that in the case of the untreated
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coculture, the fungal growth exceeded 100% of the field-of-view (24 h) developing three-dimensional,
multilayered hyphal mass. Additionally, the average hyphal area was 10-fold higher than in the case
of the lowest MICAN concentration applied. The antifungal effect of MICAN (and DIMICAN) is
also presented in the supporting video files Movie S1 and Movie S2. Despite effective fungal growth
inhibitory of MICAN, the treated HaCat cells showed no sign of damage under 24 h.
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Figure 1. Hyphal growth of C. albicans in the presence of methylamino-5-isocyanonaphthalene 
(MICAN). Time-lapse microscopic images (a) of HaCat cells infected by C. albicans in the presence of 
different concentrations of MICAN and the corresponding hyphal growth curves (b) determined from 
the average individual hyphal area of C. albicans. (Areas were measured instead of lengths due to the 
hyphal ramifications). 
2.2. Antifungal Susceptibility Testing–Determination of Structure-Activity Relationship 
ICAN has 3 key moieties, namely the amino, naphthalene and isonitrile. To find out which ones 
of them are essential for the antifungal behavior and to design more efficient derivatives, comparative 
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Figure 1. Hyphal growth ofC. albicans in the presence of methylamino-5-isocyanonaphthalene (MICAN).
Time-lapse microscopic images (a) of HaCat cells infected by C. albicans in the presence of different
concentrations of MICAN and the corresponding hyphal growth curves (b) determined from the
average individual hyphal area of C. albicans. (Areas were measured instead of lengths due to the
hyphal ramifications).
2.2. Antifungal Susceptibility Testing–Determination of Structure-Activity Relationship
ICAN has 3 key moieties, namely the amino, naphthalene and isonitrile. To find out which
ones of them are essential for the antifungal behavior and to design more efficient derivatives,
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comparative studies were carried out, where one of the moieties was exchanged or eliminated. The
modification/synthetic strategy is summarized in Figure 2. All ICAN derivatives were tested against
C. albicans SC5314, C. krusei ATCC 6258 and Candida parapsilosis ATCC 22019. Table 1 summarizes
the minimum inhibitory concentrations (MICs) of the ICAN derivatives. The antifungal agents were
dissolved in 100% DMSO and diluted further in RPMI-1640 (with L-glutamine but without bicarbonate)
and buffered to pH 7.0 with 0.165 M morpholinopropanesulfonic acid (MOPS). MICs were read visually
after 48 h incubation at 35 ◦C using the partial (50%) inhibition (for ICAN derivatives) (PI) and total
inhibition (for amphotericin B (AMB) and ICAN derivatives) (TI) criteria. MICs were determined at
least twice.
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Table 1. In vitro susceptibilities of C. albicans SC5314, C. parapsilosis ATCC 22019, and C. krusei ATCC
6258 to various ICAN derivatives determined by the Clinical & Laboratory Standards Institute (CLSI)
broth microdilution method. MICs were read using the partial (MICPI) and total inhibition (MICTI)
criteria. [22]. For the full names and structures of the compounds please refer to Figure 2 and the
experimental section of this paper. The lowest MICs are indicated in red. For the MICTI values of AMB
for these Candida strains please refer to Table 2.
Compound Candida Species MICPI (µg/mL) MICTI (µg/mL)
ICAN
C. albicans SC5314 1.25 5
C. parapsilosis ATCC 22019 0.3 0.6
C. krusei ATCC 6258 0.6 2.5
MICAN
C. albicans SC5314 0.3 1.25
C. parapsilosis ATCC 22019 0.15 0.75
C. krusei ATCC 6258 0.15 1.25
EICAN
C. albicans SC5314 0.6 2.5
C. parapsilosis ATCC 22019 0.6 1.25
C. krusei ATCC 6258 0.6 1.25
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Table 1. Cont.
Compound Candida Species MICPI (µg/mL) MICTI (µg/mL)
PICAN
C. albicans SC5314 0.6 2.5
C. parapsilosis ATCC 22019 0.6 1.75
C. krusei ATCC 6258 0.15 2.5
DIMICAN
C. albicans SC5314 ≤0.04 0.6
C. parapsilosis ATCC 22019 0.15 0.6
C. krusei ATCC 6258 0.15 0.3
DIN
C. albicans SC5314 0.3 0.6
C. parapsilosis ATCC 22019 0.3 0.6
C. krusei ATCC 6258 0.3 0.6
DAN
C. albicans SC5314 50 100
C. parapsilosis ATCC 22019 50 100
C. krusei ATCC 6258 50 100
PDI
C. albicans SC5314 50 100
C. parapsilosis ATCC 22019 50 100
C. krusei ATCC 6258 50 100
Based on the data of Table 1 it can be concluded that even the simplest amino-isocyanonaphthalene
molecule ICAN has good antifungal effect with MICTI values between 0.6–5 µg/mL. The starting
compound 1,5-diaminonaphthalene (DAN) proved to be completely ineffective against Candida (MICTI
> 100 µg/mL), therefore we can conclude that the isonitrile group is essential for the antifungal effect.
Next the free amino group of ICAN was converted to isonitrile resulting 1,5-diisocyanonaphthalene
(DIN), which showed similar (or higher) antifungal activity (MICTI = 0.6 µg/mL) compared to that
of ICAN. However, the largely nonpolar and rigid aromatic structure of DIN significantly limits
its solubility in polar solvents, such as water. We previously also encountered solubility problems
with DIN, when we tried to determine its fluorescent properties [14]. Nevertheless, DIN may also
become an effective antifungal drug after solving the solubility issues with proper formulation. The
naphthalene core of DIN was exchanged to phenylene to obtain 1,4-phenylenediisocyanide (PDI). In
contrast to DIN, PDI proved to be completely ineffective (MICTI > 100µg/mL), which means that the
naphthalene core is also essential for the antifungal behavior (Figure 2.). To increase the efficacy of
ICAN derivatives, the substitution of the amino group followed. The alkylation of the amino group
increases the dipolarity of the molecules, however at the same time it reduces their ability to form
H-bonding as an H-bond donor. Monomethylation (MICAN) led to lowered MICTI values (0.75–1.25
µg/mL), however the use of longer alkyl chains, such as ethyl and propyl (EICAN and PICAN) proved
to be not so effective (MICTI = 1.25–2.5 µg/mL and 1.75–2.5 µg/mL, respectively), maybe due to steric
hinderance. The lowest MIC values were obtained in the case of DIMICAN (MICPI ≤ 0.04 µg/mL and
MICTI = 0.3–0.6 µg/mL), the dimethylated ICAN derivative. It should be noted that the MICs did not
vary significantly for most of the compounds under investigation, only in the case of ICAN was a
broader range observed (9-fold variation for ICAN (MIC = 0.6–5 µg/mL). For further tests we chose
one of the most effective ICAN derivative, DIMICAN which has no cytotoxic effect [15,20]. To test
the “real life” behavior of DIMICAN it was tested for in vitro susceptibility against clinical isolates
collected from patients at the Clinics of the University of Debrecen. Table 2 summarizes the MICs of
the new antifungal agent DIMICAN.
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Table 2. In vitro susceptibilities of Candida isolates to DIMICAN and amphotericin B (AMB), determined by CLSI broth microdilution method. MICs were
determined according to the CLSI M27-A3 using the partial (MICPI) and total inhibition (MICTI) criteria. [22]. MICs were read visually after 48 h incubation
at 35 ◦C using the partial (50%) inhibition (for DIMICAN) (PI) and total inhibition (for AMB and DIMICAN) (TI) criteria. MICs were determined at least twice.
DIMICAN = 1,1-N-dimethylamino-5-isocyanonaphthalene.
C. albicans C. tropicalis C. krusei
Isolate MICPI(µg/mL)
MICTI
(µg/mL)
AMB
MICTI
(µg/mL)
Isolate MICPI(µg/mL)
MICTI
(µg/mL)
AMB
MICTI
(µg/mL)
Isolate MICPI(µg/mL)
MICTI
(µg/mL)
AMB
MICTI
(µg/mL)
ATCC 10231 ≤0.04 0.3 0.25 ATCC 750 0.15 1.25 0.5 ATCC 6258 0.15 0.3 1
456 ≤0.04 0.6 0.5 579 0.08 0.6 0.5 749 0.08 0.08 1
665 ≤0.04 0.6 1 622 0.08 0.3 1 1853 0.08 0.3 1
685 ≤0.04 0.6 0.25 1776 0.08 0.3 1 4364 ≤0.04 0.15 1
720 ≤0.04 0.6 0.5 2467 0.15 1.25 0.5 5029 ≤0.04 0.08 1
963 ≤0.04 0.6 0.5 3014 0.08 0.6 0.5 5072 0.08 0.3 1
1544 ≤0.04 0.6 0.25 5115 0.08 1.25 0.5 25504 0.08 0.3 0.5
8658 ≤0.04 0.6 1 5806 0.08 0.15 0.25 34987 ≤0.04 0.08 1
3666 ≤0.04 0.6 0.5
C. glabrata C. parapsilosis
Isolate MICPI(µg/mL)
MICTI
(µg/mL)
AMB
MICTI
(µg/mL)
Isolate MICPI(µg/mL)
MICTI
(µg/mL)
AMB
MICTI
(µg/mL)
ATCC 90030 0.15 0.3 0.5 ATCC 22019 0.15 0.6 0.5
14408 ≤0.04 0.08 0.5 4133 0.08 0.08 0.25
14559 ≤0.04 0.3 0.5 9613 0.15 0.15 0.25
22394 ≤0.04 0.3 0.5 10252 ≤0.04 0.08 0.5
23429 ≤0.04 0.3 1 18154 0.08 0.6 0.5
23481 0.08 1.25 1 27001 ≤0.04 0.3 0.25
27643 0.08 0.3 0.5
28557 ≤0.04 0.6 0.5
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Amphotericin B susceptibility of the isolates was also tested, and their MICTI values were not
higher than 2 µg/mL in each case. DIMICAN MICPI values were same or significantly lower compared
to MICTI for all tested five Candida species. The lowest MICs were noticed in case of C. albicans.
2.3. Mouse Model of Infection and Antifungal Therapy
In the model of acute invasive candidiasis, neutropenic mice were infected via the lateral tail
vein with C. albicans 3666 isolate (3 × 104 cfu/ mouse) to establish an acute infection. All untreated
control animals died within six days. DIMICAN (5 mg/kg) prolonged the survival period of animals
compared to non-treated infected controls (p < 0.05; 80 versus 0% survivors at day 7 post-infection;
Figure 3a). It should be noted, however, that DIMICAN was administered as intraperitoneal injection
which contained DIMICAN as an emulsion in reagent grade olive oil and water. The effect of the pure
vehicle (oil/water emulsion) was tested on eight-week-old mice and aside from increased weight gain
compared to the control group, no mortality was observed within five days. Proper clinical formulation
may have resulted in better survival of the treated group, however it is a complex task for this new
molecule and therefore exceeds the scope of this paper.Mo cules 2020, 25, 903 9 of 12 
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Figure 3. In vivo antifungal activity results for DIMICAN against Candida albicans 3666 isolate.
(a) Survival curves of mice infected with Candida albicans 3666 isolate. For all groups n = 10. (b) Kidney
tissue burden of immunosuppressed mice infected by Candida albicans 3666 isolate, two days after
infection. (c) Six days after infection (p < 0.05 (*); p 0.001 (**)).
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2.4. Determination of Fungal Burden
During an independent in vivo experiment, mice were infected intravenously with C. albicans
3666 isolate. The infected mice were euthanized two or six days after infection (n = 5 and 6 mice/time
point, respectively) to determine the fungal burden in the kidney. Kidney burden was analyzed using
a Kruskal–Wallis test with Dunn’s posttest for multiple comparisons [23,24]. Results of fungal burden
experiments are shown on Figs. 3b and c. Two days after infection AMB and DIMICAN had no
effect on fungal load (p > 0.05). Six days after infection AMB and DIMICAN treatment resulted in
significantly lower fungal burden compared to control: p < 0.05 (AMB); p < 0.001 (DIMICAN). It is
evident in Figure 3a,b, that on day six the fungal burden increased by an order of magnitude (from
~105 to ~106) in the case of the untreated mice, while in the case of DIMICAN it remained the same as it
was on day two. The same is valid for AMB. Based on these results it can be concluded that DIMICAN
is at least as effective in reducing the fungal burden in the kidney as amphotericin B.
3. Discussion
It was discovered that our new, original molecule: 1-amino-5-isocyanonaphthalene (ICAN) and its
derivatives exert excellent antifungal activity against a broad range ofCandida species. Structure-activity
studies based on minimum in vitro inhibitory concentration (MIC) determined for threeCandida species,
namely C. albicans, C. krusei and C. parapsilosis revealed that for the antifungal effect the naphthalene
core, the isocyano- and the amino-moieties are all necessary. It was noted that alkylation especially
methylation considerably increased the antifungal activity. However, 1,5-diisocyanonaphthalene
(DIN) also showed low MIC (MICPI = 0.3 µg/mL, MICTI = 0.6 µg/mL), but its rigid structure and
consequently its low solubility in aqueous media may limit its application. Nevertheless, proper
formulation and/or substitution with solubility enhancer groups on the naphthalene core may increase
its effectiveness. Based on MIC values (MICPI = 0.04–0.3 µg/mL, MICTI = 0.6 µg/mL) and its low
cytotoxicity 1,1-N-dimethylamino-5-isocyanonaphthalene (DIMICAN) was selected to be tested on
clinical Candida isolates. In vitro we tested it using microdilution method against Candida albicans (8
isolates), C. krusei (7 isolates), C. tropicalis (7 isolates), C. glabrata (7 isolates) and C. parapsilosis (5 isolates)
to get total minimum inhibitory concentration (MICTI) values of 0.08–1.25 µg/mL. These MIC values
are comparable or lower than that of amphotericin B for the same isolates. It is important to note that
DIMICAN was found to be effective against intrinsically fluconazole resistant C. krusei isolates, too.
The in vivo applicability of DIMICAN was tested on immunosuppressed mice and control experiments
were also conducted with amphotericin B. In the model of acute invasive candidiasis, neutropenic
mice were infected intravenously with C. albicans 3666 isolate (3 × 104 cfu/ mouse) to establish an acute
infection, and all untreated control animals died within six days. DIMICAN (5 mg/kg) prolonged
the survival period of animals compared with the survival period of non-treated infected controls,
P < 0.05; 80 versus 0% survivors at day 7 post infection. Results of fungal burden in kidney revealed
that six days after infection AMB and DIMICAN were efficient against Candida isolate: p < 0.05 (AMB);
p < 0.001 (DIMICAN). Based on these results and the easy and versatile modification of the ICANs
we hope that they have the potential to become an effective clinical lead compound family against
pathogenic fungi. As potential lead compounds, ICANs, meet one or more criteria of commercial use,
such as low cost, easy preparation and good chemical stability, for example after extensive toxicity and
time-kill studies may be used as antimycotic coatings on medical tubes and/or devices. This simple,
cheap, nontoxic and easy to prepare compound family would allow not only human treatment, but at
the same time could be used as disinfectants and/or coating which is vital against the spread of highly
virulent Candida strains.
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4. Materials and Methods
4.1. Materials
1,5-diaminonaphthalene (DAN, Aldrich, D21200) was used as received. The synthesis of the
ligands: 1-amino-5-isocyanonaphthalene (ICAN), 1-N-methylamino-5-isocyanonaphthalene (MICAN)
1-N,N-dimethylamino-5-isocyanonaphthalene (DIMICAN) and 1,5-diisocyanonaphthalene (DIN) is
found in refs.: 14 and 17.
4.2. General Method for the Synthesis of Alkylated 1-amino-5-isocyanonaphthalenes
A 250 mL round-bottomed flask, equipped with a magnetic stir bar was charged with
1-amino-5-isocyanonaphthalene (1.00 g, 5.94 mmol), potassium hydroxide (0.670 g, 11.9 mmol)
and absolute dimethyl formamide freshly distilled over phosphorus pentoxide (100 mL). Alkyliodide
(59.4 mmol)* was added to the solution, then the flask was flushed with argon and sealed with a rubber
septum. The reaction mixture was stirred at room temperature, protected from light. After two days
200 mL methylene chloride and 5% ammonia solution was added, and the solution was extracted
5 times with water, then the organic phase was dried over anhydrous magnesium sulfate. Solvent
was removed on a rotary evaporator and the residue was purified on a normal-phase silicagel filled
column, using methylene chloride: hexane (1:1) as eluent.
Ethyliodide (Sigma-Aldrich, Schnelldorf, Germany) was used to synthesize
1-ethyl-5-isocyanonaphthalene (EICAN) (yellow crystals, 370 mg, 32% yield) and diEICAN
(light green waxy compound, 90 mg, 6.8% yield). To synthesize1-propyl-5-isocyanonaphthalene
(PICAN) propyliodide (Sigma-Aldrich, Germany) was used. PICAN (light yellow waxy compound,
440 mg, 35% yield) and diPICAN (green waxy compound, 100 mg, 6.7% yield). With the excess of
alkyl iodide used the ratio of the mono- and dialkylated-product formed can be controlled.
EICAN (1-N-ethylamino-5-isocyanonaphthalene) 1H NMR (400 MHz, CDCl3) δ = 7.83 (d, J = 8.6 Hz,
1H), 7.50 (q, J = 8.6 Hz, 3H), 7.32 (dd, J = 8.5, 7.5 Hz, 1H), 6.66 (dd, J = 6.8, 1.6 Hz, 1H), 4.30 (s, 1H), 3.29
(q, J = 7.1 Hz, 2H), 1.39 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ = 166.70 (quart. Ar-NC),
144.05 (quart. Ar), 129.06 (Ar), 124.49 (Ar), 123.52 (quart. Ar), 123.21 (Ar), 121.85 (Ar), 111.48 (Ar),
105.55 (Ar), 38.69 (Ethyl–CH2–), 14.65 (Ethyl–CH3) ppm.
PICAN (1-N-propylamino-5-isocyanonaphthalene) 1H NMR (400 MHz, CDCl3) δ = 7.83 (d, J = 8.6 Hz,
1H), 7.50 (q, J = 8.6 Hz, 3H),7.32 (dd, J = 8.5, 7.5 Hz, 1H), 6.66 (dd, J = 6.4, 1.8 Hz, 1H), 4.38 (s, 1H), 3.22 (t,
J = 7.0 Hz, 2H), 1.85–1.72 (m, 2H), 1.08 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ = 166.70
(quart. Ar-NC), 144.10 (quart. Ar), 129.06 (Ar), 124.49 (Ar), 123.53 (quart. Ar), 123.19 (Ar), 121.81 (Ar),
111.36 (Ar), 105.50 (Ar), 45.96 (Propyl–CH2–), 22.51 (Propyl–CH2–), 11.81 (Propyl–CH3) ppm.
4.3. Time-lapse Microscopy and Digital Image Analysis of Cocultures of HaCaT cells and C. albicans
Human keratinocytes were grown under standard cell breeding conditions in T-25 culture vessels.
At 40% of cellular monolayer confluency the cultures were treated and observed under four parallel
custom-built inverted microscopes housed in a cell-breeding incubator. 1.5 × 105/mL C. albicans
cells were used for inoculation. Image acquisitions were carried out at 1 frame/min frequency.
Exposure-synchronized low-energy near-infrared illumination at 940 nm was used for the sake of
minimal invasivity. Image sequences were preprocessed prior analysis to eliminate flickering and
uneven illumination artefacts. Quantitative image analysis were done via NIH (US National Institutes
of Health) ImageJ v1.39d software bundle, using hyphal separation plugins. Determination of hyphal
area was preferred for precision against length, because of the frequent overlapping and ramifications
in control samples.
4.4. Clinical Isolates and Antifungal Susceptibility Testing
The tested C. albicans, C. tropicalis, C. parapsilosis, C. glabrata and C. krusei ATCC strains and clinical
isolates (collected from sterile body sites) are listed in Table 2. MICs were determined according to the
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CLSI M27-A3 [22]. Antifungal agents were dissolved in 100% DMSO and diluted further in RPMI-1640
(with L-glutamine but without bicarbonate) (Sigma, Budapest, Hungary), and buffered to pH 7.0 with
0.165 M morpholinopropanesulfonic acid (MOPS; Sigma, Budapest, Hungary). The final concentration
ranges used for AMB and ICAN derivatives were 0.125 to 4 µg/mL and 0.04 to 20 µg/mL, respectively.
Cell suspensions were prepared in RPMI 1640 medium and were adjusted to give a final inoculum
concentration of 0.5 × 103 to 2.5 × 103 cells/mL. MICs were read visually after 48-h incubation at 35 ◦C
using the partial (50%) inhibition (for ICAN derivatives) (PI) and total inhibition (for AMB and ICAN
derivatives) (TI) criteria. MICs were determined at least twice. For amphotericin B isolates with MIC
values of ≤2 mg/L were considered wild-types [25].
4.5. Mouse Model of Infection
We used 10–12 week-old female BALB/c mice for all experiments. Mice were immunosuppressed
using 150 mg/kg intraperitoneal (ip) cyclophosphamide dose (4 days prior to infection) and 100 mg/kg
ip cyclophosphamide dose (1 day prior to infection; 2 and 5 days after infection) [26]. All mice received
ceftazidime (5 mg/day subcutaneously) from days 0 to 6 after infection. Mice were given food and
water ad libitum and were monitored daily. The animals were maintained in accordance with the
Guidelines for the Care and Use of Laboratory Animals, and the experiments were approved by the
Animal Care Committee of the University of Debrecen, Debrecen, Hungary (permission no. 12/2014).
Mice were infected via the lateral tail vein with C. albicans 3666 bloodstream isolate. In the lethality
(10 mice/group) and fungal tissue burden experiments (6 mice/group) the infectious doses were 3 × 104
and 104 cfu/ mouse, respectively. These doses led to 100% and 0% mortality, respectively by day 6 after
infection among untreated mice. Inoculum density was confirmed by plating serial dilutions onto
Sabouraud dextrose agar (SDA) plates.
4.6. Antifungal Therapy
AMB (Fungizone, commercial preparation) and DIMICAN treatment in a 0.5-mL bolus was
started 1 h after infection. The doses were 1 mg AMB and 5 mg DIMICAN (in olive oil/water (o/w)
emulsion) per kg body weight. All antifungals were administered intraperitoneally once daily for 5
consecutive days.
4.7. Determination of Fungal Burden
Infected mice were euthanized 2 and 6 days after infection (n = 6 mice/time point) to determine
the fungal burden in the kidney. The organs were aseptically removed, weighed, homogenized in
sterile saline, serially diluted 10-fold in sterile saline. Aliquots of 0.1 mL of the undiluted and diluted
homogenates were plated onto SDA, and the colony count was determined after 48 h. Colony-forming
units (CFUs) were determined after 48 h of incubation at 37 ◦ C and results were expressed as cfus/g
tissue [26]. The lower limit of detection was 50 cfu/g tissue. Kidney burden was analyzed using a
Kruskal–Wallis test with Dunn’s posttest for multiple comparisons [23,24].
4.8. Statistical Test
Survival effects were analyzed by the Kaplan–Meier log-rank test. Kidney burden was analyzed
using a Kruskal–Wallis test with Dunn’s posttest for multiple comparisons [23,24].
Supplementary Materials: The following are available online. Movie S1: Time lapse video of HaCat cells infected
with Candida Albicans in the presence of different concentrations of MICAN. Movie S2: Time lapse video of HaCat
cells infected with Candida Albicans in the presence of different concentrations of DIMICAN.
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